Oseltamivir-resistant influenza A and B viruses pre- and postantiviral therapy in children and young adults with cancer

Pediatric Infectious Disease Journal

Volumn 30, Issue 4, 2011, Pages 284-288

  Carr, Silvana ^a   Ilyushina, Natalia A ^c   Franks, John ^a   Adderson, Elisabeth E ^a,b   Caniza, Miguela ^a   Govorkova, Elena A ^a   Webster, Robert G ^a,b  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^b UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^c DARTMOUTH MEDICAL SCHOOL   (United States)

Author keywords

Children; Immunosuppression; Influenza; Oseltamivir; Resistance

Indexed keywords

AMANTADINE; OSELTAMIVIR; PROTEIN M2; VIRUS SIALIDASE; ZANAMIVIR;

ADOLESCENT; ADULT; ANTIVIRAL RESISTANCE; ANTIVIRAL SUSCEPTIBILITY; ANTIVIRAL THERAPY; ARTICLE; CANCER PATIENT; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; ENZYME INHIBITION; FEMALE; GENE SEQUENCE; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IC 50; IMMUNOSUPPRESSIVE TREATMENT; INFLUENZA; INFLUENZA A; INFLUENZA B; INFLUENZA VIRUS A; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; VIRUS ISOLATION; VIRUS MUTATION; VIRUS SHEDDING;

EID: 79954818141     PISSN: 08913668     EISSN: 15320987     Source Type: Journal    
DOI: 10.1097/INF.0b013e3181ff863b     Document Type: Article

References (42)

1. Thompson WW, Shay DK, Weintraub E, et al. Mortality associated with influenza and respiratory syncytial virus in the United States. JAMA. 2003;289:179-186. (Pubitemid 36068705)
2. Thompson WW, Shay DK, Weintraub E, et al. Influenza-associated hospitalizations in the United States. JAMA. 2004;292:1333-1340. (Pubitemid 39223224)
3. Ison MG, Mills J, Openshaw P, et al. Current research on respiratory viral infections: Fourth International Symposium. Antiviral Res. 2002;55:227-278. (Pubitemid 34718127)
4. Yousuf HM, Englund J, Couch R, et al. Influenza among hospitalized adults with leukemia. Clin Infect Dis. 1997;24:1095-1099. (Pubitemid 27249007)
5. Gubareva LV, Kaiser L, Hayden FG. Influenza virus neuraminidase inhibitors. Lancet. 2000;355:827-835. (Pubitemid 30128828)
6. Gubareva LV. Molecular mechanisms of influenza virus resistance to neuraminidase inhibitors. Virus Res. 2004;103:199-203. (Pubitemid 38649080)
7. Aoki FY, Boivin G, Roberts N. Influenza virus susceptibility and resistance to oseltamivir. Antivir Ther. 2007;12:603-616. (Pubitemid 47235503)
8. Abed Y, Baz M, Boivin G. Impact of neuraminidase mutations conferring influenza resistance to neuraminidase inhibitors in the N1 and N2 genetic backgrounds. Antivir Ther. 2006;11:971-976. (Pubitemid 44955172)
9. Bright RA, Shay DK, Shu B, et al. Adamantane resistance among influenza A viruses isolated early during the 2005-2006 influenza season in the United States. JAMA. 2006;295:891-894.
10. Colman PM, Hoyne PA, Lawrence MC. Sequence and structure alignment of paramyxovirus hemagglutinin-neuraminidase with influenza virus neuraminidase. J Virol. 1993;67:2972-2980. (Pubitemid 23143664)
11. Wang C, Takeuchi K, Pinto LH, et al. Ion channel activity of influenza A virus M2 protein: characterization of the amantadine block. J Virol. 1993;67:5585-5594. (Pubitemid 23241395)
12. Ison MG, Gubareva LV, Atmar RL, et al. Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis. 2006;193:760-764.
13. Frank AL, Taber LH, Wells CR, et al. Patterns of shedding of myxoviruses and paramyxoviruses in children. J Infect Dis. 1981;144:433-441. (Pubitemid 12249626)
14. Whitley RJ, Hayden FG, Reisinger KS, et al. Oral oseltamivir treatment of influenza in children. Pediatr Infect Dis J. 2001;20:127-133. (Pubitemid 32151932)
15. Hayden FG, Treanor JJ, Fritz RS, et al. Use of the oral neuraminidase inhibitor oseltamivir in experimental human influenza: randomized controlled trials for prevention and treatment. JAMA. 1999;282:1240-1246. (Pubitemid 29468495)
16. Nicholson KG, Aoki FY, Osterhaus AD, et al. Efficacy and safety of oseltamivir in treatment of acute influenza: a randomised controlled trial. Neuraminidase Inhibitor Flu Treatment Investigator Group. Lancet. 2000;355:1845-1850. (Pubitemid 30311875)
17. Memoli MJ, Jagger BW, Dugan VG, et al. Recent human influenza A/H3N2 virus evolution driven by novel selection factors in addition to antigenic drift. J Infect Dis. 2009;200:1232-1241.
18. Six HR, Webster RG, Kendal AP, et al. Antigenic analysis of H1N1 viruses isolated in the Houston metropolitan area during four successive seasons. Infect Immun. 1983;42:453-458. (Pubitemid 14230233)
19. Yen HL, Ilyushina NA, Salomon R, et al. Neuraminidase inhibitor-resistant recombinant A/Vietnam/1203/04 (H5N1) influenza viruses retain their replication efficiency and pathogenicity in vitro and in vivo. J Virol. 2007;81:12418-12426. (Pubitemid 350085855)
20. Hoffmann E, Stech J, Guan Y, et al. Universal primer set for the full-length amplification of all influenza A viruses. Arch Virol. 2001;146:2275-2289. (Pubitemid 34682391)
21. Zambon M, Hayden FG. Position statement: global neuraminidase inhibitor susceptibility network. Antiviral Res. 2001;49:147-156. (Pubitemid 32322468)
22. Bright RA, Medina MJ, Xu X, et al. Incidence of adamantane resistance among influenza A (H3N2) viruses isolated worldwide from 1994 to 2005: a cause for concern. Lancet. 2005;366:1175-1181. (Pubitemid 41393595)
23. Ferraris O, Kessler N, Lina B. Sensitivity of influenza viruses to zanamivir and oseltamivir: a study performed on viruses circulating in France prior to the introduction of neuraminidase inhibitors in clinical practice. Antiviral Res. 2005;68:43-48. (Pubitemid 41338581)
24. Gubareva LV, Webster RG, Hayden FG. Comparison of the activities of zanamivir, oseltamivir, and RWJ-270201 against clinical isolates of influenza virus and neuraminidase inhibitor-resistant variants. Antimicrob Agents Chemother. 2001;45:3403-3408. (Pubitemid 33107853)
25. McKimm-Breschkin J, Trivedi T, Hampson A, et al. Neuraminidase sequence analysis and susceptibilities of influenza virus clinical isolates to zanamivir and oseltamivir. Antimicrob Agents Chemother. 2003;47:2264-2272. (Pubitemid 36753582)
26. Monto AS, McKimm-Breschkin JL, Macken C, et al. Detection of influenza viruses resistant to neuraminidase inhibitors in global surveillance during the first 3 years of their use. Antimicrob Agents Chemother. 2006;50:2395-2402. (Pubitemid 43993177)
27. Lackenby A, Thompson CI, Democratis J. The potential impact of neuraminidase inhibitor resistant influenza. Curr Opin Infect Dis. 2008;21:626-638.
28. Centers for Disease Control and Prevention (CDC). Update: influenza activity - United States, August 30, 2009-March 27, 2010, and composition of the 2010-11 influenza vaccine. Morb Mortal Wkly Rep. 2010;59:423-430.
29. Gubareva LV, Matrosovich MN, Brenner MK, et al. Evidence for zanamivir resistance in an immunocompromised child infected with influenza B virus. J Infect Dis. 1998;178:1257-1262.
30. Weinstock DM, Gubareva LV, Zuccotti G. Prolonged shedding of multidrug-resistant influenza A virus in an immunocompromised patient. N Engl J Med. 2003;348:867-868. (Pubitemid 36245772)
31. Baz M, Abed Y, McDonald J, et al. Characterization of multidrug-resistant influenza A/H3N2 viruses shed during 1 year by an immunocompromised child. Clin Infect Dis. 2006;43:1555-1561. (Pubitemid 44901897)
32. Johny AA, Clark A, Price N, et al. The use of zanamivir to treat influenza A and B infection after allogeneic stem cell transplantation. Bone Marrow Transplant. 2002;29:113-115. (Pubitemid 34144842)
33. Roberts NA. Treatment of influenza with neuraminidase inhibitors: virological implications. Philos Trans R Soc Lond B Biol Sci. 2001;356:1895-1897. (Pubitemid 34099095)
34. Treanor JJ, Hayden FG, Vrooman PS, et al. Efficacy and safety of the oral neuraminidase inhibitor oseltamivir in treating acute influenza: a randomized controlled trial. US Oral Neuraminidase Study Group. JAMA. 2000;283:1016-1024. (Pubitemid 30112215)
35. Moscona A. Neuraminidase inhibitors for influenza. N Engl J Med. 2005;353:1363-1373. (Pubitemid 41362704)
36. Okomo-Adhiambo M, Demmler-Harrison GJ, Deyde VM, et al. Detection of E119V and E119I mutations in influenza A (H3N2) viruses isolated from an immunocompromised patient: challenges in diagnosis of oseltamivir resistance. Antimicrob Agents Chemother. 54:1834-1841.
37. Le QM, Kiso M, Someya K, et al. Avian flu: isolation of drug-resistant H5N1 virus. Nature. 2005;437:1108. (Pubitemid 41509341)
38. Boivin G, Goyette N. Susceptibility of recent Canadian influenza A and B virus isolates to different neuraminidase inhibitors. Antiviral Res. 2002;54:143-147. (Pubitemid 34327680)
39. Mungall BA, Xu X, Klimov A. Surveillance of influenza isolates for susceptibility to neuraminidase inhibitors during the 2000-2002 influenza seasons. Virus Res. 2004;103:195-197. (Pubitemid 38649079)
40. Sugaya N, Mitamura K, Yamazaki M, et al. Lower clinical effectiveness of oseltamivir against influenza B contrasted with influenza A infection in children. Clin Infect Dis. 2007;44:197-202. (Pubitemid 46079980)
41. Hatakeyama S, Sugaya N, Ito M, et al. Emergence of influenza B viruses with reduced sensitivity to neuraminidase inhibitors. JAMA. 2007;297:1435-1442. (Pubitemid 46556469)
42. Hurt AC, Barr IG, Durrant CJ, et al. Surveillance for neuraminidase inhibitor resistance in human influenza viruses from Australia. Commun Dis Intell. 2003;27:542-547.